Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Exodus Bio is a biotechnology company specializing in advanced exosome isolation and purification technologies. The company's proprietary EXODUS platform utilizes ultrasonic nano-filtration and negative-pressure oscillation to isolate high-purity, high-yield exosomes from various biological fluids, including plasma, urine, and cell culture media. Their technology supports research, diagnostics, and large-scale manufacturing of exosome-based therapies, providing a label-free and automated alternative to traditional isolation methods like ultracentrifugation. The company's systems are designed to accelerate the development of nanomedicines and diagnostic biomarkers by providing a more efficient way to isolate extracellular vesicles (EVs), lipid nanoparticles (LNPs), and virus-like particles (VLPs).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Exodus Travels.